Background

Define a ligand, the angiopoetic-like proteins/receptor family, Toll-like receptors (TLRs), fibroblast growth factors (FGFs), NFkB-based molecular map of human vasculature, which have been useful in functional genomics, proteomics, and stem cell to translate stem cell-based and nuclease based genome engineering technologies into clinical applications to integrate immunology, stem cell with cancer research and be the basis to understand the biological mechanisms that guide the reprogramming of cells, detecting disease and development of cleaver agents and targeted therapeutic regenerative medicine.

Method

To understand the molecular mechanisms that govern somatic and pluripotent human stem cell development, both through the characterisation of molecular pathways and genomic targets that regulate hematopoietic and pluripotent stem cells differentiation through the use of: high-performance cell-based assay and qPCR technologies (Human Stem Cell Signaling PCR Array, RT2 Profiler PCR Arrays & Assays, qBiomarker Copy Number Arrays, ELISA arrays Transcription factor reporter assays,) andnovel in vivo models for cellular/tissue regeneration through xeno-transplantation.The Capillary Thermodynamic DSMA-4 andHDX MS, SR7500DC Surface Plasmon Resonance Systemwill be used to illustrate the mechanism and the structure of the angiopoetic-like proteins /receptor family, Toll-like receptors (TLRs), Fibroblast growth factors (FGFs) and NFkB. Then, by means of Capillary Electrophoresis, and automation in combination with high throughput screening methods, the cleaver DNA, RNA aptamers with a wide range of predefined values of Kd, high selectivity and response will be generated. Also, by using microRNA quantification by qRT-PCR and TALENTM technology reporter assys (shRNA/siRNA function, chemokine levels, microRNA quantification) new therapeutics such as novel zinc-finger DNA binding proteinsand epigenetic silencing of DDR genes,microRNAs modulate hematopoietic and pluripotent stem cells that modify the genome and antibodies which target angiogenesis of receptors, angiopoetic-like proteins /receptor family, Toll-like receptors (TLRs), fibroblast growth factors (FGFs),will be created.

Results

By means of capillary electrophoresis, and automation in combination with high throughput screening methods, thecleaver DNA, RNA aptamers with a wide range of predefined values ofKd, high selectivity and response will be generated. Also by using, microRNA quantification by qRT-PCR and TALENTM technology reporter assys(shRNA/siRNA function, chemokine levels, microRNA quantification) new therapeutics such as novel zinc-finger DNA binding proteinsand epigenetic silencing of DDR genes,microRNAs modulate hematopoietic and pluripotent stem cells that modify the genome and antibodies which target angiogenesis of receptors, angiopoetic-like proteins /receptor family, Toll-like receptors (TLRs), fibroblast growth factors (FGFs),will be created.

Conclusion

Using high-performance cell-based assay, qPCR nuclease based genome engineering technologies will allow to inhibit receptors, graft rejection in transplantation (a complex module-specific inflammatory transcriptional response) destroy cancer cells by increasing of antibody-antigen interactions, develop abundant sources of human hematopoietic progenitors, and cleaver treatments to eliminate tumour. A ligand, the angiopoetic-like proteins /receptor family, Toll-like receptors (TLRs) , fibroblast growth factors (FGFs), NFkB -based molecular map of human vasculature will be defined. By this way, the human stem cell and nuclease based genome engineering technologies will translate into clinical applications,opena new field ofbiology integratingimmunology, stem cell with cancer research and turn out to be the basis for the development of the biological mechanisms that guide the reprogramming of cells, therapeutics targeting many different disorders, including human type I diabetes, AIDS, autoimmune, cancer and other diseases.